Intervention Review

Golimumab for rheumatoid arthritis

  1. Jasvinder A Singh1,*,
  2. Shahrzad Noorbaloochi2,
  3. Gurkirpal Singh3

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 20 JAN 2010

Assessed as up-to-date: 10 NOV 2009

DOI: 10.1002/14651858.CD008341


How to Cite

Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008341. DOI: 10.1002/14651858.CD008341.

Author Information

  1. 1

    Minneapolis VA Medical Center, Medicine, Minneapolis, Minnesota, USA

  2. 2

    Minneapolis VA Medical Center and University of Minnesota, Medicine, Minneapolis, MN, USA

  3. 3

    Stanford University School of Medicine, Division of Gastroenterology and Hepatology, Palo Alto, CA, USA

*Jasvinder A Singh, Medicine, Minneapolis VA Medical Center, 1 Veterans Drive, Rheumatology (111R), Minneapolis, Minnesota, 55417, USA. jasvinder.md@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 JAN 2010

SEARCH

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens

or

Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Patient Access

Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.